e-learning
resources
Glasgow 2004
Monday 06.09.2004
Chemotherapy, targeted therapies costs and outcomes
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Gefitinib in the non small cell lung cancer treatment: contribution to prolongation and quality of survival
M. Pesek, G. Krakorova (Plzen, Czech Republic)
Source:
Annual Congress 2004 - Chemotherapy, targeted therapies costs and outcomes
Session:
Chemotherapy, targeted therapies costs and outcomes
Session type:
Thematic Poster Session
Number:
1949
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Pesek, G. Krakorova (Plzen, Czech Republic). Gefitinib in the non small cell lung cancer treatment: contribution to prolongation and quality of survival. Eur Respir J 2004; 24: Suppl. 48, 1949
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Rates of treatment response and median survival in advanced non small cell lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004
Tobacco exposure and survival in non small cell lung cancer patients treated with erlotinib
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC)
Source: Eur Respir J 2004; 24: Suppl. 48, 672s
Year: 2004
Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008
Does long treatment delay affect survival in metastatic non-small cell lung cancer
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021
Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation
Source: Annual Congress 2011 - Quality management for lung cancer patients
Year: 2011
Long-term survival of the patients with advanced non small cell lung carcinomas after induction chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005
Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)?
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003
Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002
Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005
Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population
Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Year: 2017
Impact of radiotherapy on survival rates in chemotherapy treated small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Non small cell lung cancer: options and outcome of treatment beyond second line
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
Source: Eur Respir J 2010; 35: 202-215
Year: 2010
One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept